$XNPT (Xenoport, Inc.)

$XNPT {{ '2016-05-23T20:04:08+0000' | timeago}} • Announcement

Pharma company $XNPT it agreed to be acquired by Arbor Pharmaceuticals for $7.03 per share in cash, or a total equity value of approx. $467MM. The transaction, which has been unanimously approved by both the Board of Directors, is expected to close in the 3Q16. Centerview Partners is serving as exclusive financial advisor to $XNPT.

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$EBS {{ '2017-10-06T16:07:34+0000' | timeago}} • Announcement

$EBS completed its acquisition of Sanofi’s ACAM2000 (Smallpox Vaccine, Live) business, which includes ACAM2000, cGMP live viral manufacturing facility and office and warehouse space, both in Canton, Massachusetts, and a cGMP viral fill/finish facility in Rockville, Maryland.

$EBS {{ '2017-10-04T12:11:30+0000' | timeago}} • Announcement

$EBS has been awarded a contract valued at up to approximately $25MM by the U.S. Department of State to supply TROBIGARD auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning.

$EBS {{ '2017-10-03T13:27:49+0000' | timeago}} • Announcement

Life sciences firm $EBS completed the acquisition of raxibacumab, an FDA-approved human monoclonal antibody for the treatment of inhalational anthrax, from $GSK. The company plans a $130MM contract with the Biomedical Advanced Research and Development Authority to supply the product to the US Strategic National Stockpile through November 2019.

$EBS {{ '2017-10-02T11:57:04+0000' | timeago}} • Announcement

Life sciences company $EBS said it has completed a $200MM syndicated senior secured credit facility. The new five-year facility replaces the company’s previous $100MM facility that was scheduled to expire in December 2018. The new facility enhances Emergent’s financial flexibility by increasing the capacity to drive growth through acquisitions.

$LLY {{ '2017-09-28T21:06:48+0000' | timeago}} • Announcement

FDA approves $LLY's breast cancer drug Verzenio (abemaciclib), which will compete with $PFE's Ibrance and $NVS' Kisqali drugs. Verzenio works by blocking certain molecules involved in promoting the growth of cancer cells. The National Cancer Institute estimated that approximately 252,710 women will be diagnosed with breast cancer this year.

$PFE {{ '2017-09-27T12:44:41+0000' | timeago}} • Announcement

$PFE declared 4Q17 dividend of $0.32 per share, payable Dec. 1, 2017, to shareholders of record at the close of business on Nov. 10, 2017. This cash dividend will be the 316th consecutive quarterly dividend paid by the company.

$PFE {{ '2017-09-27T12:19:24+0000' | timeago}} • Announcement

$PFE receives approval for BAVENCIO to treat Merkel cell carcinoma (MCC), a rare type of skin cancer, in Japan. This is the first-ever treatment indicated for curatively unresectable MCC and first anti-PD-L1 to be available in Japan.

$EBS {{ '2017-09-25T11:45:12+0000' | timeago}} • Announcement

$EBS received a 5-year follow-on contract valued at up to about $171MM from the U.S. Department of Defense (DoD) to supply RSDL (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military. The RSDL Kit is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin.

$PRGO {{ '2017-09-21T14:01:01+0000' | timeago}} • Announcement

Healthcare firm $PRGO said the FDA has approved the Abbreviated New Drug Application for its painkiller Exalgo-32mg. Perrigo expects to launch the Exalgo-32mg extended-release tablets by the end of this month. Exalgo is indicated for the management of moderate to severe pain in opioid-tolerant patients.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$PRGO {{ '2017-09-18T13:18:23+0000' | timeago}} • Announcement

$PRGO has received tentative approval from the US FDA for the generic version of Acanya topical gel 1.2%/ 2.5%, for the topical treatment of acne in patients 12 years or older.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$PRGO {{ '2017-08-21T17:07:39+0000' | timeago}} • Announcement

$PRGO got the final nod from the FDA for the store brand OTC equivalent of Nexium 24HR (esomeprazole magnesium) capsules, to treat frequent heartburns occurring 2 or more days a week.  It also reached a settlement of patent litigation with AstraZeneca allowing for the store brand OTC equivalent of Nexium 24HR capsules to launch in Sept, 2017.

$PFE {{ '2017-08-17T19:23:27+0000' | timeago}} • Announcement

The US FDA has approved $PFE's rare blood cancer drug BESPONSA. The U.S. labeling for BESPONSA includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease (VOD) and increased risk of post-HSCT non-relapse mortality.

$PRGO {{ '2017-08-16T13:22:34+0000' | timeago}} • Announcement

$PRGO received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Mycolog II Cream. This is indicated for the treatment of cutaneous candidiasis, which is a skin fungal infection causing a red, itchy rash. $PRGO anticipates launching this product in 4Q17.

$PRGO {{ '2017-08-10T17:56:52+0000' | timeago}} • Infographic

$PRGO Perrigo Company plc Earnings AlphaGraphic: Q2 2017 Highlights

Recent Transcripts

PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
ABEO (Abeona Therapeutics Inc.)
Tuesday, August 22 2017 - 2:00pm
PRGO (Perrigo Company Public Limited Company)
Thursday, August 10 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
INFU (InfuSystem Holdings, Inc.)
Wednesday, August 9 2017 - 8:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, August 9 2017 - 12:00pm
EBS (Emergent BioSolutions, Inc.)
Thursday, August 3 2017 - 9:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PRGO (Perrigo Company Public Limited Company)
Wednesday, May 31 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
INFU (InfuSystem Holdings, Inc.)
Friday, May 12 2017 - 1:00pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, May 10 2017 - 12:00pm
EBS (Emergent BioSolutions, Inc.)
Thursday, May 4 2017 - 9:00pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm
ABEO (Abeona Therapeutics Inc.)
Monday, April 10 2017 - 2:00pm
INFU (InfuSystem Holdings, Inc.)
Wednesday, March 22 2017 - 2:00pm

AlphaGraphics you may like